EQUITY.GURU podcast - Investing for millennials and madmen

Welcome once again to Equity Guru’s Short and Sweet where we distill our in-depth interviews into solid nuggets of gold, enabling you to drink down the cream of each conversation in one delectable 5-minute gulp. In this week’s three-part episode, we are drawing from The Jody Vance Experience where Jody speaks with Brigadier Gold (BRG.V) president, CEO and director, Ranjeet Sundher, PredictMedix (PMED.C) CEO, Dr. Rahul Kushwah and EarthRenew (ERTH.C) CEO and director, Keith Driver. Listen in! Full disclosure: Brigadier Gold, PredictMedix and EarthRenew are Equity.Guru marketing clients.

Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Here are the highlights!

Welcome to the second installment! Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Listen in!

Developing new prescription medicine for market is a costly and oftentimes, a futile endeavor as drugmakers can spend up to $2.6 billion only to see 12% of their candidates gain approval. When Pfizer fails on two out of three new drugs, retail investors have grown leery of the space, but companies like Aequus Pharmaceuticals (AQS.V) have found a way to bypass this massive regulatory and financial bottleneck by seeking out existing drugs approved in other countries and bringing them to Canada for market approval. Spending 12-18 months rather than the standard 8-10 years for new drug approval, Aequus also benefits from low fixed costs that allow the company to profitably operate in a relatively small marketplace such as Canada in niche areas including neurology, ophthalmology and transplant. Positioned for growth with $2.0 million cash in the till, Aequus is a steady bet in an uncertain industry. As such, Equity Guru’s own Chris Parry spoke with company CEO and chairman, Doug Janzen, to get a better look at Aequus unique de-risked approach and its potential for investors. Tune in!

Time for part 2! Sixth Wave Innovations (SIXW.C), a world leader in molecular detection and extraction, is working to disrupt the market for Covid rapid testing as well as mineral extraction for gold mining and last but not least, cannabis extraction. Equity Guru's own Chris Parry spoke with company president, CEO and founder, Jonathan Gluckman, PhD., to get an inside look at the company and what potential it holds for investors. Tune in!

Sixth Wave Innovations (SIXW.C), a world leader in molecular detection and extraction, is working to disrupt the market for Covid rapid testing as well as mineral extraction for gold mining and last but not least, cannabis extraction. Equity Guru's own Chris Parry spoke with company president, CEO and founder, Jonathan Gluckman, PhD., to get an inside look at the company and what potential it holds for investors. Tune in!

This is the final segment where Pure Extracts Technologies (PULL.C) CEO, Ben Nikolaevsky, speaks with Equity Guru's own, Chris Parry, to outline the companies cross market potential in plant-based extraction. Tune in!

It's not all about legal cannabis anymore, Pure Extracts Technologies (PULL.C) CEO, Ben Nikolaevsky, speaks with Equity Guru's own, Chris Parry, to outline the companies cross market potential in plant-based extraction. Tune in!

Ahead of Kwesst's initial public offering (IPO), Equity Guru's own Chris Parry talks with the company's Executive Chairman David E. Luxton to gives us a closer look into what the company does and where they're headed.

KWESST is a Canadian military tech company that is “making dumb weapons smart” by developing proprietary technology for the military and homeland security markets. The total Global Defense Budget is estimated at USD $1.8 Trillion in 2020 and the market is expected to grow to USD $2.3 Trillion by 2028. “Thirteen conflicts are identified as top priorities for the United States,” states The Council on Foreign relations. KWESST has a diversified product line, based on a single core...

Small caps in Canada, especially in tech, are full of faux-companies. You know,the kind where the problem being solved isn’t really a problem, and the“technology” being advertised is actually five years old. PredictMedix (PMED.C) isn’t one of them. The last time I wrote about PredictMedix, I made an argument about: Since then, the stock has been pumped. Listen in as Arth talks with Kapil Raval!

KWESST is a Canadian military tech company that is “making dumb weapons smart”. KWESST develops and markets proprietary technology to sell into the military and homeland security market. Conceptually and financially, KWESST has a tight, elegant structure. Publicly listed military tech companies typically use a shot gun approach to product development: Body armour? We got it. Armed robotics? We got it. Amphibious rifles? Just one – or a whole case? KWESST has a diversified product line,...

On April 14, 2020 Last Mile Holdings (MILE.V) announced a new delivery service for restaurants, grocery stores, and other local businesses. It’s a smart adaptive mechanism to offer local business an alternative to being gouged by food delivery companies. Gotcha’s sit-down scooters and/or e-bikes will be available to these hard-hit vendors for $15 per day to deliver goods to customers – allowing local businesses to cut out 3rd-party delivery services, which typically charge 20 to 30 percent...

Last Mile Holdings (MILE.V) suffered the misfortune of beginning life as a publicly traded company on March 9, 2020 – a day when the Great Stock Market Crash of 2020 began – the DJIA falling 2,013 points that day to 23,851. On March 5, 2020, Last Mile announced the acquisition of Gotcha Mobility, focusing on university campuses in the U.S. Gotcha has been a micro-mobility leader for 10 years, starting with electric rideshare vehicles and pedal bikes, then expanding into e-bikes,...

At 6:30 a.m. Monday, March 9, 2020 Last Mile Holdings (MILE.V) will begin its life as a publicly traded company. What’s “Last Mile” about? Think Zipcar but with scooters and e-bikes. This service is “on trend”. Unlike previous generations, Millennials don’t perceive car ownership as hip. They prefer access to ownership. Case in point: Millennials account for about 23% of the general population but comprise more than 50% of Zipcar's members. Renting an electric scooter is...

Yield Growth (BOSS.C) has developed a portfolio of cannabis-based “wellness formulas” – under the Urban Juve brand – with a dedicated range of skin and body care formulations.” On January 23, 2010, Yield Growth announced that Urban Juve's hemp infused lip balm was placed in hundreds of thousands of IPSY Glam Bags, garnering 15,000 consumer reviews with an overall consumer rating of 4.5 stars out of 5. Through its subsidiaries, Yield Growth has over 200 proprietary beauty, wellness,...

Yield Growth (BOSS.C) has developed a portfolio of cannabis-based “wellness formulas” – under the Urban Juve brand – with a dedicated range of skin and body care formulations.” The approach is founded in Ayurveda, one of the oldest holistic systems in the world. Urban Juve, has signed agreements for distribution in Canada, Colombia, Brazil, Costa Rica, Panama, Argentina, El Salvador, Ecuador, Peru, Greece, Cyprus, Bulgaria, Romania and Serbia. Yield Growth’s Wright & Well brands are...

Jeanette VanderMarel is well-known in the world of Canadian legal cannabis. One of the forces behind T-God (TGOD.T), Jeanette made a name for herself, but not necessarily for her achievements but for the timing of her departures from both TGod and 48North (NRTH.V). Both companies were in bad shape as she left, in fact, the last suffered crop failure after VanderMarel's departure when she had assured the media that all was well, leaving some reporters and shareholders with a bad taste in...

Isracann BioSciences (IPOT) is the first pure pot play growing in the Promised Land. You may not think this middle east nation state is a tactical choice when it comes to legal weed, but Israel leads the world in medical cannabis research with some researchers joking they are going to write the Torah of cannabis. Isracann is one of the early international players in Israel's cannabis revolution which at this point is legal to smoke but with some stiff caveats. Smoke it in public and you...

Web 3.0 is still being defined but experts believe it will create a deeply indexed information superhighway not only serving its users with a unique experience based on preference, but it will also support an army of artificially intelligent virtual agents capable of analyzing petabytes of unstructured data and returning actionable results. Sounds brilliant, but hard realities like the one-size-fits all cloud solutions offered by AWS and the relative immutability of the speed of light, our...